memo inOncology – Congress Report ESMO 2019

 Volver  Ver
memo inOncology – Congress Report ESMO 2019
 PDF   24   10/2020
 Ver

A global digest on approaches in advanced solid tumors

Rating

Rate this publication

Publicaciones relacionadas

BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer
BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer
Safety and efficacy of long-term exposure (LTE) to tislelizumab in chinese patients with advanced solid tumors
Safety and efficacy of long-term exposure (LTE) to tislelizumab in chinese patients with advanced solid tumors
Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer
Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer
 Volver